EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Qualification Criteria of Gene Therapy for Haemophilia—Opinion of the EAHAD Gene Therapy Working Group

Wolfgang Miesbach iD, Ana Boban iD, Pratima Chowdary iD, Michiel Coppens, Victor Jimenez-Yuste iD, Robert Klamroth iD, Greta Mulders iD, Miguel Crato, Flora Peyvandi iD

Haemophilia · 2025-09 · 31 (5) · 966-972

DOI: 10.1111/hae.70090 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Haemophilia, online erschienen am 17.07.2025. Verfasst von Wolfgang Miesbach und 8 weiteren Autor:innen. Beteiligte Einrichtung: Medical Clinic 2, Institute of Transfusion Medicine, University Hospital Frankfurt, Frankfurt, Germany. Hauptthemen laut MEDLINE: Hemophilia A, Genetic Therapy. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Following the approval of the first gene therapies for haemophilia, it is essential to develop an optimal infrastructure for the administration of gene therapy. This can be ensured by identifying the criteria for the definition of treatment centres (hub centres) and follow‐up centres (spoke centres), as well as establishing effective cooperation between them.

Methods

The interdisciplinary members of the EAHAD Gene Therapy Working Group answered a survey to define requirements for centres participating in gene therapy care, addressing aspects such as product administration, coagulation parameter monitoring, and long‐term safety surveillance.

Results

The majority support the implementation of standardised protocols. Hub centres are expected to maintain high standards of quality and flexibility, possess pharmacist expertise, ensure regulatory compliance, and have experience in gene therapy Spoke centres should be certified haemophilia centres, access to hepatologists and providing 24‐h support. Prior to gene therapy, spoke centres manage initial patient interactions, while hub centres handle complex care needs. Post‐therapy, both centres can monitor factor levels and liver health. However, hub centres are responsible for managing immunosuppression and facilitating specialist consultations. Collaboration between both centres is crucial for data sharing and the assessment and resolution of adverse events, emphasising the importance of timely test results and regular liver imaging.

Conclusion

The survey results highlight essential criteria for the safe and effective delivery of gene therapy through a structured hub‐and‐spoke model. These include accreditation, clinical trial experience, access to specialized healthcare professionals, and the establishment of standard operating procedures for monitoring and managing adverse events.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hemophilia AGenetic TherapyHumansSurveys and Questionnaires

Stichwörter der Autor:innen

gene therapyhaemophiliahaemophilia centrehub and spoke centrequalification criteria

Autor:innen und Institutionen

  • Medical Clinic 2, Institute of Transfusion Medicine, University Hospital Frankfurt, Frankfurt, Germany.
  • Haemophilia Centre, Department of Haematology, University Hospital Centre Zagreb, Zagreb, Croatia.
  • University of Zagreb School of Medicine, Zagreb, Croatia.
  • Katharine Dormandy Haemophilia and Thrombosis Centre, Royal Free Hospital, London, UK.
  • Hemophilia Treatment Center, Department of Vascular Medicine, Amsterdam UMC location University of Amsterdam, Amsterdam, Netherlands.
  • Amsterdam Cardiovascular Sciences, Pulmonary Hypertension & Thrombosis, Amsterdam, the Netherlands.

ORCID-Profile: Wolfgang Miesbach, Ana Boban, Pratima Chowdary, Victor Jimenez-Yuste, Robert Klamroth, Greta Mulders, Flora Peyvandi

Zitieren

APA

Miesbach, W., Boban, A., Chowdary, P., Coppens, M., Jimenez-Yuste, V., Klamroth, R., Mulders, G., Crato, M., & Peyvandi, F. (2025). Qualification Criteria of Gene Therapy for Haemophilia—Opinion of the EAHAD Gene Therapy Working Group. Haemophilia, 31(5), 966-972. https://doi.org/10.1111/hae.70090

Vancouver

Miesbach W, Boban A, Chowdary P, Coppens M, Jimenez-Yuste V, Klamroth R, et al. Qualification Criteria of Gene Therapy for Haemophilia—Opinion of the EAHAD Gene Therapy Working Group. Haemophilia. 2025;31(5):966-972. doi:10.1111/hae.70090

BibTeX
@article{Miesbach2025,
  author = {Miesbach, Wolfgang and Boban, Ana and Chowdary, Pratima and Coppens, Michiel and Jimenez-Yuste, Victor and Klamroth, Robert and Mulders, Greta and Crato, Miguel and Peyvandi, Flora},
  title = {Qualification Criteria of Gene Therapy for Haemophilia—Opinion of the EAHAD Gene Therapy Working Group},
  journal = {Haemophilia},
  year = {2025},
  volume = {31},
  number = {5},
  pages = {966--972},
  doi = {10.1111/hae.70090}
}
Kostenlos starten →